HCG Versus Spontaneous LH in Intrauterine Insemination (IUI ) Cycles

This study has been completed.
Sponsor:
Information provided by:
Universitair Ziekenhuis Brussel
ClinicalTrials.gov Identifier:
NCT01414673
First received: August 5, 2011
Last updated: August 10, 2011
Last verified: August 2011

August 5, 2011
August 10, 2011
April 2009
July 2011   (final data collection date for primary outcome measure)
ongoing pregnancy rate [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01414673 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
HCG Versus Spontaneous LH in Intrauterine Insemination (IUI ) Cycles
Spontaneous Triggering of Ovulation vs. Administration of Human Chorionic Gonadotropin in Patients Undergoing Intrauterine Insemination: a Prospective Randomized Study.

We recently reported the superiority of the natural cycle to a natural cycle controlled by the administration of human chorionic gonadotropin (hCG) for planning the frozen-thawed embryo transfer cycles, demonstrating a probable negative impact of exogenous hCG on endometrial receptivity.Based on the above findings we conducted the first prospective study that assesses whether there is a difference in pregnancy rate after intrauterine insemination (IUI) in a natural cycle with spontaneous luteinizing hormone (LH) rise compared to natural cycles controlled by hCG for final ovulation.

Not Provided
Interventional
Phase 0
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Spontaneous Triggering of Ovulation vs. Administration of Human Chorionic Gonadotropin in Patients Undergoing IUI
Drug: HCG
5000 IU
  • spontaneous LH
    Intervention: Drug: HCG
  • Experimental: HCG
    Intervention: Drug: HCG
Kosmas IP, Tatsioni A, Fatemi HM, Kolibianakis EM, Tournaye H, Devroey P. Human chorionic gonadotropin administration vs. luteinizing monitoring for intrauterine insemination timing, after administration of clomiphene citrate: a meta-analysis. Fertil Steril. 2007 Mar;87(3):607-12. Epub 2006 Dec 14.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
August 2011
July 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • age ≤ 36 years,
  • regular menstrual cycles,
  • body mass index (BMI) between 18 and 29 kg/m²,
  • basal levels of FSH (≤ 12 IU/l),
  • estradiol (≤ 80 pg/ml) and progesterone (≤ 1.6ng/ml) on day one of the cycle, normal hysterosalpingography (maximum 3 months prior starting the cycle).
  • The use of donor sperm was also accepted as inclusion criteria.

Exclusion Criteria:

  • PCOS
  • endometriosis
Female
18 Years to 36 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT01414673
WAS11
Yes
Devroey Paul, CRG
Universitair Ziekenhuis Brussel
Not Provided
Not Provided
Universitair Ziekenhuis Brussel
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP